10x Genomics financials
$90.04+1.74%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $642.8M | $610.8M | $618.7M | $516.4M | $490.5M | $298.8M | $245.9M |
| Gross profit | $443.9M | $414.5M | $409.3M | $396.0M | $416.4M | $240.4M | $184.9M |
| Gross margin | 69.1% | 67.9% | 66.2% | 76.7% | 84.9% | 80.4% | 75.2% |
| Operating income | -$61.0M | -$194.6M | -$265.3M | -$167.9M | -$52.3M | -$534.1M | -$30.6M |
| Net income | -$43.5M | -$182.6M | -$255.1M | -$166.0M | -$58.2M | -$542.7M | -$31.3M |
| Net margin | −6.8% | −29.9% | −41.2% | −32.1% | −11.9% | −181.6% | −12.7% |
| Diluted EPS | $-0.35 | $-1.52 | $-2.18 | $-1.46 | $-0.53 | $-5.37 | $-0.80 |
| EBITDA | -$74.7M | -$158.7M | -$229.8M | -$134.9M | -$24.7M | -$513.9M | -$22.0M |
| Operating cash flow | $136.1M | $6.7M | -$15.2M | -$33.6M | -$21.4M | -$217.9M | $34.6M |
| Free cash flow | $130.1M | -$5.7M | -$63.8M | -$165.3M | -$122.7M | -$254.6M | -$8.1M |
| Diluted shares | 124.7M | 120.5M | 117.2M | 113.9M | 110.3M | 101.2M | 39.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $474.0M | $344.1M | $359.3M | $219.7M | $587.4M | $663.6M |
| Short-term investments | $49.4M | $49.3M | $29.4M | $210.2M | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.04B | $918.6M | $965.1M | $1.03B | $1.02B | $929.3M |
| Total liabilities | $245.0M | $208.5M | $224.1M | $223.2M | $201.3M | $190.3M |
| Shareholders' equity | $796.3M | $710.1M | $741.0M | $805.7M | $817.6M | $739.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology